

Amivantamab-lazertinib ups survival in EGFR-mutated advanced lung cancer

July 1 2024, by Elana Gotkine



For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line treatment, according to a study [published](#) online June 26 in the *New England Journal of Medicine*.

Byoung C. Cho, M.D., Ph.D., from the Yonsei Cancer Center in Seoul, South Korea, and colleagues conducted a phase 3 trial involving patients with previously untreated EGFR-mutated, locally advanced or metastatic NSCLC randomly allocated to receive amivantamab-lazertinib (open-label), osimertinib (blinded), or lazertinib (blinded) in a 2:2:1 ratio (429, 429, and 216 patients, respectively).

The researchers found that the median [progression-free survival](#) was significantly longer in the amivantamab-lazertinib group than in the osimertinib group (23.7 versus 16.6 months; hazard ratio for [disease progression](#) or death, 0.70). An objective response was observed in 86 and 85% of patients in the amivantamab-lazertinib and osimertinib groups, respectively; among patients with a confirmed response, the median response duration was 25.8 and 16.8 months, respectively.

The hazard ratio for death did not differ significantly in a planned interim overall survival analysis of amivantamab-lazertinib versus osimertinib. EGFR-related toxic effects were the predominant adverse events. The incidence of discontinuation of all agents due to treatment-related adverse events was 10 and 3% with amivantamab-lazertinib and osimertinib, respectively.

"We found that progression-free survival was significantly improved with amivantamab-lazertinib as compared with osimertinib as first-line treatment for EGFR-mutated advanced NSCLC," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Janssen, which manufactures amivantamab and lazertinib and funded the study.

More information: Byoung C. Cho et al, Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC, *New England Journal of Medicine* (2024). [DOI:](#)

[10.1056/NEJMoa2403614](https://doi.org/10.1056/NEJMoa2403614)

© 2024 [HealthDay](https://www.healthday.com). All rights reserved.

Citation: Amivantamab-lazertinib ups survival in EGFR-mutated advanced lung cancer (2024, July 1) retrieved 11 September 2024 from <https://medicalxpress.com/news/2024-07-amivantamab-lazertinib-ups-survival-egfr.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.